{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:28:33Z","timestamp":1761182913459,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Shionogi & Co., Ltd."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.jiac.2014.11.009","type":"journal-article","created":{"date-parts":[[2014,11,26]],"date-time":"2014-11-26T16:37:47Z","timestamp":1417019867000},"page":"194-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir (II): A pediatric drug use investigation"],"prefix":"10.1016","volume":"21","author":[{"given":"Takuji","family":"Komeda","sequence":"first","affiliation":[]},{"given":"Shingo","family":"Ishii","sequence":"additional","affiliation":[]},{"given":"Yumiko","family":"Itoh","sequence":"additional","affiliation":[]},{"given":"Yasuyuki","family":"Ariyasu","sequence":"additional","affiliation":[]},{"given":"Masaki","family":"Sanekata","sequence":"additional","affiliation":[]},{"given":"Takayoshi","family":"Yoshikawa","sequence":"additional","affiliation":[]},{"given":"Jingoro","family":"Shimada","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2014.11.009_bib1","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1128\/AAC.00474-10","article-title":"Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection","volume":"54","author":"Kohno","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2014.11.009_bib2","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1128\/AAC.01718-10","article-title":"Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients","volume":"55","author":"Kohno","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2014.11.009_bib3","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1128\/AAC.00360-11","article-title":"Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection","volume":"55","author":"Kohno","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2014.11.009_bib4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1128\/AAC.00132-11","article-title":"Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection","volume":"56","author":"Sugaya","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2014.11.009_bib5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1086\/345909","article-title":"Influenza A and B virus infections in children","volume":"36","author":"Peltola","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2014.11.009_bib6","unstructured":"Reports on side effects in teenager with respect to cases with downfall and jumping off after taking oseltamivir. http:\/\/www.mhlw.go.jp\/houdou\/2007\/03\/h0321-1.html. [accessed 08.01.14]"},{"key":"10.1016\/j.jiac.2014.11.009_bib7","unstructured":"Abnormal behavior after taking oseltamivir. http:\/\/www.mhlw.go.jp\/houdou\/2007\/03\/h0320-1.html. [accessed 08.01.14]"},{"key":"10.1016\/j.jiac.2014.11.009_bib8","unstructured":"Investigation on the circumstances surrounding the occurrence of symptoms accompanying influenza. http:\/\/www.mhlw.go.jp\/shingi\/2009\/06\/dl\/s0616-4g.pdf. [accessed 08.01.14]"},{"key":"10.1016\/j.jiac.2014.11.009_bib9","unstructured":"Investigation on the gathering of information on abnormal behavior (occurring) at the time of acquiring influenza-like disease (Report of the 2009\/2010 Season). http:\/\/www.mhlw.go.jp\/shingi\/2009\/06\/dl\/s0616-4h.pdf. [accessed 08.01.14]"},{"key":"10.1016\/j.jiac.2014.11.009_bib10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ijantimicag.2012.06.017","article-title":"Safety of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate in post-marketing surveillance","volume":"40","author":"Kashiwagi","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2014.11.009_bib11","series-title":"48th annual meeting of the Infectious Diseases Society of America (IDSA); 10\/22\/2010; Vancouver, BC","first-page":"765","article-title":"Neutropenia is not related to neuraminidase inhibitor (NAI) therapy of influenza in phase 2 and 3 controlled clinical trials","author":"Hernandez","year":"2010"},{"key":"10.1016\/j.jiac.2014.11.009_bib12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10156-012-0481-9","article-title":"Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance","volume":"19","author":"Kashiwagi","year":"2013","journal-title":"J\u00a0Infect Chemother"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X14004024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X14004024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:53:56Z","timestamp":1761159236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X14004024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S1341321X14004024"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2014.11.009","relation":{},"ISSN":["1341-321X"],"issn-type":[{"type":"print","value":"1341-321X"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir (II): A pediatric drug use investigation","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2014.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}